---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053351"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2026-08-05T20:09:55+00:00"
generated_at: "2026-08-05T20:11:46.898860+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology Q2 net income $80.1M on Astellas deal; cash $1.01B

## Summary
- Net income of $80.1M ($0.48 diluted EPS) vs net loss of $111.0M in Q2 2025.
- Revenue $238.9M, primarily from $240M Astellas upfront payment; cash $1.01B.
- Phase 2 SOLSTICE: 88% of CHD patients achieved undetectable HDV RNA at Week 96.
- Phase 3 ECLIPSE 1 topline data expected Q4 2026; ECLIPSE 2 fully enrolled.
- Appointed Timothy Coughlin to Board and as Audit Committee Chair.

## SEC filing metadata
- accession: 0001628280-26-053351
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2026-08-05T20:09:55+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828026053351/0001628280-26-053351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828026053351/vir-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053351
- JSON: https://secwatch.observer/filing/0001628280-26-053351.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053351.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.